Carrie L. Griffiths, Matthew R. Jackson, T. Hoke, K. Hertel
{"title":"血管紧张素II用于感染性休克治疗的最新进展","authors":"Carrie L. Griffiths, Matthew R. Jackson, T. Hoke, K. Hertel","doi":"10.1097/01.CCN.0000546307.15415.e6","DOIUrl":null,"url":null,"abstract":"Abstract: Septic shock is a condition associated with life-threatening hypoperfusion that often requires vasopressor therapy. The FDA's approval last year of angiotensin II for use in septic shock may impact current treatment. This article reviews current literature and trials about the use of angiotensin II for the treatment of septic shock.","PeriodicalId":19344,"journal":{"name":"Nursing Critical Care","volume":"13 1","pages":"30–37"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.CCN.0000546307.15415.e6","citationCount":"1","resultStr":"{\"title\":\"Angiotensin II for septic shock treatment: An update\",\"authors\":\"Carrie L. Griffiths, Matthew R. Jackson, T. Hoke, K. Hertel\",\"doi\":\"10.1097/01.CCN.0000546307.15415.e6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Septic shock is a condition associated with life-threatening hypoperfusion that often requires vasopressor therapy. The FDA's approval last year of angiotensin II for use in septic shock may impact current treatment. This article reviews current literature and trials about the use of angiotensin II for the treatment of septic shock.\",\"PeriodicalId\":19344,\"journal\":{\"name\":\"Nursing Critical Care\",\"volume\":\"13 1\",\"pages\":\"30–37\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/01.CCN.0000546307.15415.e6\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nursing Critical Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.CCN.0000546307.15415.e6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nursing Critical Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.CCN.0000546307.15415.e6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
Angiotensin II for septic shock treatment: An update
Abstract: Septic shock is a condition associated with life-threatening hypoperfusion that often requires vasopressor therapy. The FDA's approval last year of angiotensin II for use in septic shock may impact current treatment. This article reviews current literature and trials about the use of angiotensin II for the treatment of septic shock.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
